Health Products Regulatory Authority

CERTIFICATE NUMBER: ***2019/25698_2***

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER [1, 2]

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Ireland confirms the following:
The manufacturer: ***Divi's Laboratories Limited***
Site address: ***Unit – 2, Chippada Village, Annavaram Post, Bheemunipatnam Mandal, Visakhapatnam District, Andhra Pradesh, 531 162, India***

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation:
Medicinal Products (Control of Manufacture) Regulations 2007 to 2013.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2019-08-30*** , it is considered that it complies with :

- The principles of GMP for active substances [3] referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

---

[1] *The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.*

[2] *Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.*

[3] *These requirements fulfil the GMP recommendations of WHO.*

Part 2

Manufacture of active substance. Names of substances subject to inspection :
LEVODOPA(en)
ORLISTAT(en)
ISAVUCONAZOLE(en)
LEVETIRACETAM(en)
RITONAVIR(en)
ABACAVIR(en)
LETERMOVIR(en)
RALTEGRAVIR POTASSIUM(en)
SITAGLIPTIN PHOSPHATE(en)
BOSENTAN MONOHYDRATE(en)
DORAVIRINE(en)
CARBIDOPA MONOHYDRATE(en)
VIGABATRIN(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : LEVODOPA

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Milling, sieving, micronization and blending 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : ORLISTAT

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Micronisation

	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : ISAVUCONAZOLE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Filtration Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : LEVETIRACETAM

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : RITONAVIR

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material

	which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : ABACAVIR

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : LETERMOVIR

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Crystallisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : RALTEGRAVIR POTASSIUM

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Salt Formation/Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for

	identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : SITAGLIPTIN PHOSPHATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Salt Formation/ Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : BOSENTAN MONOHYDRATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying/Micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : DORAVIRINE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps :

	Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : CARBIDOPA MONOHYDRATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Milling, Sieving, Micronization and Blending 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : VIGABATRIN

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying and Micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

2020-01-30

Name and signature of the authorised person of the Competent Authority of Ireland

---

Confidential
Health Products Regulatory Authority
Tel: ***Confidential***
Fax: ***Confidential***